Licain (Lidocaine Hydrochloride Monohydrate)

Licain (lidocaine) is used as a local anesthetic and anti‑arrhythmic agent in several clinical settings.

• Minor surgical procedures: provides localized numbness to facilitate painless incision and manipulation.
• Infiltration anesthesia: enables targeted nerve block for diagnostic biopsies or cosmetic procedures.
• Subcutaneous anesthesia: allows safe administration of local anesthesia for minor skin interventions.
• Ventricular arrhythmias (IV use): stabilizes cardiac electrical activity during acute arrhythmic events.

• Lidocaine blocks voltage‑gated sodium channels in neuronal and cardiac cell membranes, preventing the rapid influx of sodium ions required for depolarization. By stabilizing the membrane, it inhibits initiation and propagation of nerve impulses, producing loss of sensation. In cardiac tissue, the same sodium‑channel blockade reduces automaticity and conduction velocity, helping to suppress ventricular ectopic activity.

Lidocaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Tingling or numbness at the injection site
• Burning or stinging sensation during administration
• Light‑headedness or dizziness
• Transient hypotension

Serious or Rare Side Effects

• Methemoglobinemia leading to cyanosis
• Seizures or convulsions
• Severe cardiac arrhythmias or cardiac arrest
• Anaphylactic or severe allergic reactions

When using Licain, clinicians should observe several safety considerations to minimize risk.

• Allergic history: assess for prior hypersensitivity to amide‑type local anesthetics.
• Cardiac conduction disorders: avoid or use cautiously in patients with heart block or severe ventricular dysfunction.
• Hepatic impairment: reduce dose or monitor plasma levels in patients with significant liver disease.
• Pediatric use: calculate dose carefully based on weight and monitor for systemic toxicity.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Store at room temperature: keep below 25 °C, protect from moisture and light in the original container.

Lidocaine can interact with other medicines, altering its plasma concentration or enhancing toxicity.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine toxicity.
• CYP3A4 inhibitors (e.g., amiodarone, ketoconazole): raise systemic levels and risk of adverse effects.
• Other sodium‑channel blockers (e.g., bupivacaine, mexiletine): additive cardiac depressant effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lidocaine efficacy.
• Beta‑blockers (e.g., propranolol): can potentiate bradycardia when combined with lidocaine.